CoChat

The role of gut microbiota in cancer treatment: friend or foe?

Open access

The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.

Abstract

The gut microbiota has been implicated in cancer and shown to modulate anticancer drug efficacy. Altered gut microbiota is associated with resistance to chemo drugs or immune checkpoint inhibitors (ICIs), whereas supplementation of distinct bacterial species restores responses to the anticancer drugs. Accumulating evidence has revealed the potential of modulating the gut microbiota to enhance the efficacy of anticancer drugs. Regardless of the valuable findings by preclinical models and clinical data of patients with cancer, a more thorough understanding of the interactions of the microbiota with cancer therapy helps researchers identify novel strategy for cancer prevention, stratify patients for more effective treatment and reduce treatment complication. In this review, we discuss the scientific evidence on the role of gut microbiota in cancer treatment, and highlight the latest knowledge and technologies leveraged to target specific bacteria that contribute to tumourigenesis. First, we provide an overview of the role of the gut microbiota in cancer, establishing the links between bacteria, inflammation and cancer treatment. Second, we highlight the mechanisms used by distinct bacterial species to modulate cancer growth, immune responses, as well as the efficacy of chemotherapeutic drugs and ICIs. Third, we demonstrate various approaches to modulate the gut microbiota and their potential in translational research. Finally, we discuss the limitations of current microbiome research in the context of cancer treatment, ongoing efforts to overcome these challenges and future perspectives.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2020-321153

Cites

135 of 135 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Mechanisms used by gut bacteria to modulate anticancer drug efficacy. Bacterial species influence the efficacy of chemo drugs and immune checkpoint inhibitors via diverse mechanisms. Bacteria modulate the efficacy of 5-FU via bacterial vitamin B6, B9 and ribonucleotide metabolism. Inhibiting bacterial deoxynucleotide metabolism promotes the efficacy of 5-FU. Barnesiella intestinihominis and Enterococcus hirae play a critical role in the antitumour effect of another chemo drug, cyclophosphamide. Removing these bacterial species results in drug resistance to cyclophosphamide. Mechanistically, E. hirae translocates from the small intestine to secondary lymphoid organs and stimulates the production of pTh17 cells, whereas B. intestinihominis accumulates in the colon and promotes the infiltration of IFN-γ-producing γδT cells in cancer lesions on treatment with cyclophosphamide. In addition, Fusobacterium nucleatum acts via TLR4 and MYD88, induces a selective loss of miR-18a* and miR-4802, activates autophagy and thereby promotes chemoresistance in patients. Furthermore, the antitumour effect of anti-CTLA-4 treatment depends on Bacteroides species. Bacteroides fragilis colonises the mucosal layer, induces T helper 1 immune responses in the lymph nodes and promotes the maturation of intratumorous dendritic cells, mediating the anticancer activity of the immune checkpoint inhibitor. 5-FU, 5-fluorouracil; IFN-γ, interferon-gamma; pTh17 cells, pathogenic T helper 17 cells.
Figure 1 Mechanisms used by gut bacteria to modulate anticancer drug efficacy. Bacterial species influence the efficacy of chemo drugs and immune checkpoint inhibitors via diverse mechanisms. Bacteria modulate the efficacy of 5-FU via bacterial vitamin B6, B9 and ribonucleotide metabolism. Inhibiting bacterial deoxynucleotide metabolism promotes the efficacy of 5-FU. Barnesiella intestinihominis and Enterococcus hirae play a critical role in the antitumour effect of another chemo drug, cyclophosphamide. Removing these bacterial species results in drug resistance to cyclophosphamide. Mechanistically, E. hirae translocates from the small intestine to secondary lymphoid organs and stimulates the production of pTh17 cells, whereas B. intestinihominis accumulates in the colon and promotes the infiltration of IFN-γ-producing γδT cells in cancer lesions on treatment with cyclophosphamide. In addition, Fusobacterium nucleatum acts via TLR4 and MYD88, induces a selective loss of miR-18a* and miR-4802, activates autophagy and thereby promotes chemoresistance in patients. Furthermore, the antitumour effect of anti-CTLA-4 treatment depends on Bacteroides species. Bacteroides fragilis colonises the mucosal layer, induces T helper 1 immune responses in the lymph nodes and promotes the maturation of intratumorous dendritic cells, mediating the anticancer activity of the immune checkpoint inhibitor. 5-FU, 5-fluorouracil; IFN-γ, interferon-gamma; pTh17 cells, pathogenic T helper 17 cells.CC BY-NC · PubMed Central
Figure 2 Preclinical mouse models and sequencing data of patients with cancer are valuable tools in microbiome research that contribute to the development of novel therapeutics for patients with cancer. Preclinical mouse models are valuable tools to dissect the mechanisms of defined bacteria in the absence of microbes (germ-free mice) or in the presence of limited number of microbes (antibiotic treatment). However, limitations, such as selection bias, prevent these preclinical models from fully recapitulating the interactions between the gut microbiota and cancer cells in humans. The antibiotic treatment may select for resistant bacteria or promote fungal outgrowth, confounding the result of the experiment. Other factors, including the housing environment, the diet and the genetic background of the mice, also influence the microbial communities residing in the mice and their interaction with tumour cells or anticancer drugs. To complement these preclinical models, cancer patients’ sequencing data are examined in terms of the host genome, metabolome and immune profile before and after anticancer treatment. Together, the mouse models and meta-analysis of human sequencing data provide insights into the relationship between the gut microbiota and cancer treatment. Modulating the gut microbiota by selectively targeting cancer-associated bacteria with phages, by administering probiotics or by performing FMT, may reshape the tumour microenvironment and the host immune responses, thereby augmenting the efficacy of anticancer drugs and improving the outcome of cancer patients. FMT, faecal microbiota transplant.
Figure 2 Preclinical mouse models and sequencing data of patients with cancer are valuable tools in microbiome research that contribute to the development of novel therapeutics for patients with cancer. Preclinical mouse models are valuable tools to dissect the mechanisms of defined bacteria in the absence of microbes (germ-free mice) or in the presence of limited number of microbes (antibiotic treatment). However, limitations, such as selection bias, prevent these preclinical models from fully recapitulating the interactions between the gut microbiota and cancer cells in humans. The antibiotic treatment may select for resistant bacteria or promote fungal outgrowth, confounding the result of the experiment. Other factors, including the housing environment, the diet and the genetic background of the mice, also influence the microbial communities residing in the mice and their interaction with tumour cells or anticancer drugs. To complement these preclinical models, cancer patients’ sequencing data are examined in terms of the host genome, metabolome and immune profile before and after anticancer treatment. Together, the mouse models and meta-analysis of human sequencing data provide insights into the relationship between the gut microbiota and cancer treatment. Modulating the gut microbiota by selectively targeting cancer-associated bacteria with phages, by administering probiotics or by performing FMT, may reshape the tumour microenvironment and the host immune responses, thereby augmenting the efficacy of anticancer drugs and improving the outcome of cancer patients. FMT, faecal microbiota transplant.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 135 references

Cited by

See all 385

Metadata

Authors
Cheng, W. Y., Wu, C.-Y., & Yu, J.
Affiliations
  • Chinese University of Hong Kong (HK)
  • China Medical University (TW)
Corresponding author
Yu, Jun
Venue
Gut
Publisher
BMJ
Published
2020-08-05
Volume
69
Issue
10
Pages
1867-1876
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W3047455092
Cited by
384
References
135
Citations by year
2026: 38 · 2025: 78 · 2024: 59 · 2023: 71 · 2022: 98 · 2021: 37 · 2020: 2
FWCI
5.00
Type
journal article
Language
en
Open access
Locations
  • Gut (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
gut microbiota, cancer immunotherapy, immune checkpoint inhibitors, chemoresistance, microbiota modulation, inflammation and cancer, tumourigenesis, microbiome-targeted therapy, cancer treatment efficacy
MeSH terms
Gastrointestinal Microbiome, Antineoplastic Agents, Humans, Neoplasms, Treatment Outcome, Dysbiosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The role of gut microbiota in cancer treatment: friend or foe? https://app.cochat.ai/papers/10.1136/gutjnl-2020-321153
The paper
Cheng, W. Y., Wu, C.-Y., & Yu, J. (2020). The role of gut microbiota in cancer treatment: friend or foe? Gut. https://doi.org/10.1136/gutjnl-2020-321153

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.